バイオシミラー市場：薬剤クラス（モノクローナル抗体（アダリムマブ、インフリキシマブ、リツキシマブ、トラスツズマブ）、インスリン、エリスロポエチン、抗凝固薬、rhGH）、適応症、地域別 2028年までの世界予測

Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region Global Forecast to 2028

世界のバイオシミラー市場規模は、2023年の294億米ドルから2028年には669億米ドルに達すると予測され、予測期間中の年平均成長率は17.8%である。規制当局の承認、有利な償還政策、費用対効果の高いバイオシミラー... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年6月15日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	298	265	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のバイオシミラー市場規模は、2023年の294億米ドルから2028年には669億米ドルに達すると予測され、予測期間中の年平均成長率は17.8%である。規制当局の承認、有利な償還政策、費用対効果の高いバイオシミラーに対する需要の高まりなどの要因が市場成長を促進している。
"モノクローナル抗体製品セグメントは、予測期間中、薬剤クラス別バイオシミラー市場で最も高い成長率を占めた"
2022年、モノクローナル抗体製品セグメントはバイオシミラー市場で最大のシェアを占めたが、これは主にバイオシミラーモノクローナル抗体の価格が基準薬と比較して安価であることと、癌、自己免疫疾患、骨粗鬆症の治療におけるラボの採用増加によるものである。最も急成長しているセグメントの成長は、世界的ながんと慢性疾患の罹患率の上昇に起因している。互換インスリン製剤の承認拡大が市場に好影響を与えそうだ。
"2022年、適応症別ではがん領域が最大シェアを占める"
適応症に基づき、バイオシミラー市場は、がん、炎症性・自己免疫疾患、慢性疾患、血液疾患、成長ホルモン欠乏症、感染症、その他の適応症に区分される。がん治療薬や成長ホルモンの需要が各地域で高まっていることが、市場の成長を後押ししている。
「アジア太平洋地域はより速いペースで成長する可能性が高い。
バイオシミラー市場は、欧州、アジア太平洋、北米、中南米、中東・アフリカに区分される。APAC市場は、多数の新興プレーヤーの存在、それほど厳しくない政府規制、バイオシミラーの開発・製造・商業化のための大手および地域プレーヤー間の協力の増加により、予測期間中に最も急成長する地域セグメントとなる見込みである。
本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給側70％、需要側30
- 回答者の役職別（供給側）マネージャー - 45%、CXOおよびディレクター - 30%、エグゼクティブ - 25
- 地域別北米：40％、欧州：25％、アジア太平洋地域：20％、中南米：10％、中東・アフリカ：5
レポート掲載企業のリスト
 ノバルティスAG（スイス）
 ファイザー（米国）
 Dr. Reddy's Laboratories Ltd.(インド）
 F.ホフマン・ラ・ロシュ社（スイス）
 イーライリリー・アンド・カンパニー（米国）
 アムジェン社（米国）
 テバ・ファーマシューティカル・インダストリーズ・リミテッド（イスラエル(イスラエル）
 サムスン・バイオロジクス（韓国）
 フレゼニウス SE & Co.KGaA（ドイツ）
 ベーリンガー・インゲルハイム・インターナショナルGmbH.(ドイツ）
 STADA Arzneimittel AG（ドイツ）
 コーヘラス・バイオサイエンシズ（米国）
 富士フイルムキリンバイオロジクス（日本日本
 USV Limited（インド）、
 Amneal Pharmaceuticals LLC.米国
 セルトリオンヘルスケア（韓国）
 バイオコン（インド）
 Intas Pharmaceuticals Ltd.(インド）
 リライアンス・ライフサイエンシズ（インド）
 アメガ・バイオテック（アルゼンチン）
 アポテックス社（カナダ）
 BIOCAD（ロシア）
 mAbxience（スペイン）
 プロバイオメッド（メキシコ）
 Kashiv BioSciences, LLC（米国）、
 Formycon AG（ドイツ）
 Polpharma Biologics Group（ポーランド）
 アンファスター・ファーマシューティカルズ（米国）
 アルボテック（アイスランド）
 UCB SA（ベルギー）
調査範囲
本レポートは、バイオシミラー市場の詳細な情報を提供します。薬剤クラス、適応症、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィール、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主なメリット
本レポートは、バイオシミラー市場全体とそのサブセグメントについて、最も近似した収益数値を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- バイオシミラー市場の成長に影響を与える主な促進要因（バイオシミラーの需要増加、新規バイオシミラーの上市、高齢者人口と慢性疾患罹患率の増加、規制プロセスの簡略化と互換性）、阻害要因（製造の複雑さ）、機会（新興市場、ブロックバスター生物製剤の特許切れ、新規適応症の研究）、課題（過当競争と規制上の課題）の分析。
- 製品開発/イノベーション：新たに上市された製品に関する詳細な洞察、バイオシミラー市場のパイプライン分析。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは、さまざまな地域のバイオシミラー市場を分析しています。
- 市場の多様化：バイオシミラー市場における新規サービス、未開拓の地域、最近の開発、投資に関する情報を網羅的に提供します。
- 競合他社の評価：Novartis AG（スイス）、Pfizer Inc.（米国）、Dr. Reddy's Laboratories Ltd.（インド）、F. Hoffmann, Inc.(Ltd.（インド）、F. Hoffmann-La Roche Ltd.（スイス）、Eli Lilly & Company（米国）、Amgen Inc.

ページTOPに戻る

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
FIGURE 1 BIOSIMILARS MARKET SEGMENTATION 34
1.3.1 YEARS CONSIDERED 34
1.4 CURRENCY CONSIDERED 35
1.5 LIMITATIONS 35
1.6 STAKEHOLDERS 35
1.7 SUMMARY OF CHANGES 36
1.8 RECESSION IMPACT 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
FIGURE 2 RESEARCH DESIGN 37
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY DATA 39
FIGURE 3 BIOSIMILARS MARKET: BREAKDOWN OF PRIMARIES 39
2.2 MARKET SIZE ESTIMATION 40
FIGURE 4 BIOSIMILARS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 40
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 41
FIGURE 6 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE ANALYSIS AND SEGMENTAL ANALYSIS, 2022 42
FIGURE 7 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE FOR DRUG CLASS & INDICATION, 2022 43
2.2.1 INSIGHTS FROM PRIMARIES 45
FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS 45
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 45
2.3 GROWTH RATE ASSUMPTIONS 46
FIGURE 10 BIOSIMILARS MARKET: CAGR PROJECTIONS, 2023–2028 46
FIGURE 11 BIOSIMILARS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 47
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 12 DATA TRIANGULATION METHODOLOGY 48
2.5 RESEARCH ASSUMPTIONS 48
2.6 RISK ANALYSIS 49
2.7 BIOSIMILARS MARKET: RECESSION IMPACT ANALYSIS 49
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2027 (% GROWTH) 50
TABLE 2 US HEALTH EXPENDITURE, 2019–2027 (USD MILLION) 50
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 50
3 EXECUTIVE SUMMARY 51
FIGURE 13 BIOSIMILARS MARKET, BY DRUG CLASS, 2023 VS. 2028 (USD MILLION) 51
FIGURE 14 BIOSIMILARS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 52
FIGURE 15 BIOSIMILARS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 52
4 PREMIUM INSIGHTS 54
4.1 BIOSIMILARS MARKET OVERVIEW 54
FIGURE 16 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH 54
4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS AND COUNTRY (2022) 55
FIGURE 17 MONOCLONAL ANTIBODIES AND US TO DOMINATE NORTH AMERICAN MARKET 55
4.3 BIOSIMILARS MARKET: GEOGRAPHICAL SNAPSHOT 56
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
FIGURE 19 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
TABLE 4 BIOSIMILARS MARKET: IMPACT ANALYSIS 58
5.2.1 DRIVERS 58
5.2.1.1 Increasing demand for biosimilars 58
5.2.1.2 Launch of novel biosimilars 59
FIGURE 20 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015 TO 2022 59
5.2.1.3 Rising geriatric population and chronic disease incidence 60
FIGURE 21 GERIATRIC POPULATION, BY REGION, 2020 VS. 2030 VS. 2050 (MILLION) 60
FIGURE 22 ESTIMATED NUMBER OF NEW CANCER CASES FROM 2020 TO 2030 61
FIGURE 23 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION) 61
5.2.1.4 Abbreviated regulatory approval process and interchangeability 62
TABLE 5 APPROVED BIOSIMILARS WITH INTERCHANGEABLE DESIGNATION 62
FIGURE 24 COMPARISON OF REFERENCE PRODUCTS, BIOSIMILARS, AND INTERCHANGEABLE PRODUCTS 63
5.2.2 RESTRAINTS 64
5.2.2.1 Complexities in manufacturing 64
TABLE 6 COMPARISON OF DRUG DEVELOPMENT PROCESSES, BY TYPE 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Emerging markets 64
5.2.3.2 Patent expiries of blockbuster biologics and research into new indications 65
TABLE 7 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY 66
5.2.4 CHALLENGES 66
5.2.4.1 High competition and regulatory challenges 66
5.3 VALUE CHAIN ANALYSIS 67
FIGURE 25 VALUE CHAIN ANALYSIS FOR BIOSIMILARS 67
5.4 ECOSYSTEM MARKET MAP 70
FIGURE 26 ECOSYSTEM MARKET MAP FOR BIOSIMILARS 70
5.5 PORTER’S FIVE FORCES ANALYSIS 70
TABLE 8 BIOSIMILARS MARKET: PORTER’S FIVE FORCES ANALYSIS 70
5.5.1 THREAT OF NEW ENTRANTS 71
5.5.2 THREAT OF SUBSTITUTES 71
5.5.3 BARGAINING POWER OF SUPPLIERS 71
5.5.4 BARGAINING POWER OF BUYERS 71
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 72
5.6 REGULATORY LANDSCAPE 72
TABLE 9 BIOSIMILARS MARKET: REGULATORY LANDSCAPE 72
TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS 74
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 14 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
5.7 KEY CONFERENCES AND EVENTS, 2023 78
TABLE 15 BIOSIMILARS MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023 78
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 78
FIGURE 27 KEY STAKEHOLDERS IN BUYING PROCESS 78
FIGURE 28 INFLUENCE OF END USERS ON BUYING PROCESS 79
5.9 PATENT ANALYSIS 79
5.10 PIPELINE ANALYSIS 80
5.11 PRICING ANALYSIS 81
TABLE 16 BIOSIMILAR PRICE, BY INDICATION AND REGION 81
5.12 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 82
6 BIOSIMILARS MARKET, BY DRUG CLASS 83
6.1 INTRODUCTION 84
TABLE 17 BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 84
6.2 MONOCLONAL ANTIBODIES 84
TABLE 18 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 85
TABLE 19 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 20 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 21 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 22 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 87
6.2.1 INFLIXIMAB 87
6.2.1.1 Infliximab to dominate mAbs market 87
TABLE 23 BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 24 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 25 EUROPE: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 26 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021–2028 (USD MILLION) 89
6.2.2 RITUXIMAB 90
6.2.2.1 Rising incidences of autoimmune diseases and cancer to boost market growth 90
TABLE 27 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2021–2028 (USD MILLION) 90
TABLE 28 NORTH AMERICA: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 29 EUROPE: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 30 ASIA PACIFIC: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021–2028 (USD MILLION) 92
6.2.3 TRASTUZUMAB 92
6.2.3.1 Increasing breast cancer prevalence to drive market growth 92
TABLE 31 BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 32 NORTH AMERICA: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 33 EUROPE: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 34 ASIA PACIFIC: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021–2028 (USD MILLION) 94
6.2.4 ADALIMUMAB 95
6.2.4.1 Loss of patent exclusivity to drive research 95
TABLE 35 FDA APPROVAL AND EU LAUNCH STATUS OF BIOSIMILARS TO HUMIRA 95
TABLE 36 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 37 NORTH AMERICA: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 38 EUROPE: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 39 ASIA PACIFIC: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021–2028 (USD MILLION) 97
6.2.5 OTHER MONOCLONAL ANTIBODIES 98
TABLE 40 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 41 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 42 EUROPE: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 43 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 100
6.3 GRANULOCYTE COLONY-STIMULATING FACTOR 100
6.3.1 LAUNCH OF BIOSIMILARS TO PROMOTE MARKET GROWTH 100
TABLE 44 LIST OF APPROVED BIOSIMILARS FOR G-CSF 101
TABLE 45 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 46 NORTH AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 47 EUROPE: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 48 ASIA PACIFIC: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021–2028 (USD MILLION) 103
6.4 INSULIN 104
6.4.1 INCREASING INCIDENCE OF DIABETES TO DRIVE MARKET 104
TABLE 49 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 50 NORTH AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 51 EUROPE: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 52 ASIA PACIFIC: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021–2028 (USD MILLION) 106
6.5 ERYTHROPOIETIN 106
6.5.1 RISING INCIDENCE OF BLOOD DISORDERS TO AUGMENT MARKET GROWTH 106
TABLE 53 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN 107
TABLE 54 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 55 NORTH AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 56 EUROPE: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 57 ASIA PACIFIC: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021–2028 (USD MILLION) 109
6.6 RECOMBINANT HUMAN GROWTH HORMONE 109
6.6.1 INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS TO PROPEL MARKET 109
TABLE 58 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2021–2028 (USD MILLION) 110
TABLE 59 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 60 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 61 ASIA PACIFIC: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021–2028 (USD MILLION) 111
6.7 ETANERCEPT 112
6.7.1 APAC TO WITNESS HIGHEST GROWTH IN ETANERCEPT MARKET 112
TABLE 62 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 63 NORTH AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 64 EUROPE: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 65 ASIA PACIFIC: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021–2028 (USD MILLION) 113
6.8 FOLLITROPIN 114
6.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET 114
TABLE 66 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 67 NORTH AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 68 EUROPE: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 69 ASIA PACIFIC: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021–2028 (USD MILLION) 115
6.9 TERIPARATIDE 116
6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST DEMAND 116
TABLE 70 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 71 NORTH AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 72 EUROPE: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 73 ASIA PACIFIC: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021–2028 (USD MILLION) 117
6.10 INTERFERONS 118
6.10.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 118
TABLE 74 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 75 ASIA PACIFIC: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.11 ANTICOAGULANTS 119
6.11.1 WIDE RANGE OF APPLICATIONS TO DRIVE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS 119
TABLE 76 BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 77 NORTH AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 78 EUROPE: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 79 ASIA PACIFIC: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021–2028 (USD MILLION) 121
6.12 OTHER DRUG CLASSES 121
TABLE 80 BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 81 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2021–2028 (USD MILLION) 122
7 BIOSIMILARS MARKET, BY INDICATION 123
7.1 INTRODUCTION 124
TABLE 82 BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 124
7.2 ONCOLOGY 124
7.2.1 INCREASED APPROVALS AND LAUNCH OF BIOSIMILARS IN ONCOLOGY TO DRIVE MARKET 124
TABLE 83 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 84 NORTH AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 85 EUROPE: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 86 ASIA PACIFIC: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 127
7.3 INFLAMMATORY & AUTOIMMUNE DISEASES 127
7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO INCREASE DISEASE INCIDENCE 127
TABLE 87 BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 88 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 89 EUROPE: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 90 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 129
7.4 CHRONIC DISEASES 129
7.4.1 HIGH BURDEN OF CVD AND DIABETES WORLDWIDE TO DRIVE MARKET GROWTH 129
TABLE 91 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 92 NORTH AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 93 EUROPE: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 94 ASIA PACIFIC: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 132
7.5 BLOOD DISORDERS 132
7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND 132
TABLE 95 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 96 NORTH AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 97 EUROPE: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 98 ASIA PACIFIC: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 134
7.6 GROWTH HORMONE DEFICIENCY 135
7.6.1 RISING USE OF BIOSIMILARS FOR TREATMENT TO SUPPORT MARKET GROWTH 135
TABLE 99 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 100 NORTH AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 101 EUROPE: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 102 ASIA PACIFIC: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021–2028 (USD MILLION) 137
7.7 INFECTIOUS DISEASES 137
7.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES TO GROW RAPIDLY IN ASIA PACIFIC 137
TABLE 103 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 104 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 138
7.8 OTHER INDICATIONS 139
TABLE 105 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 139
TABLE 106 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 107 EUROPE: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 108 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 141
8 BIOSIMILARS MARKET, BY REGION 142
8.1 INTRODUCTION 143
TABLE 109 BIOSIMILARS MARKET, BY REGION, 2021–2028 (USD MILLION) 143
8.2 EUROPE 143
TABLE 110 EUROPE: LIST OF APPROVED BIOSIMILARS 144
FIGURE 29 EUROPE: BIOSIMILARS MARKET SNAPSHOT 147
TABLE 111 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 112 EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 148
TABLE 113 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 114 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 149
8.2.1 GERMANY 150
8.2.1.1 Germany to dominate European biosimilars market 150
TABLE 115 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 151
TABLE 116 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 117 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 152
8.2.2 UK 152
8.2.2.1 Increasing adoption of biosimilars to boost market 152
TABLE 118 UK: LIST OF APPROVED BIOSIMILARS 153
TABLE 119 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 163
TABLE 120 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 121 UK: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 164
8.2.3 FRANCE 164
8.2.3.1 Rising geriatric population to drive market growth 164
TABLE 122 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 165
TABLE 123 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 124 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 166
8.2.4 ITALY 166
8.2.4.1 Favorable government policies to propel adoption of biosimilars 166
TABLE 125 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 167
TABLE 126 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 127 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 168
8.2.5 SPAIN 169
8.2.5.1 Favorable patient incentives to promote biosimilar use 169
TABLE 128 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 170
TABLE 129 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 130 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 171
8.2.6 REST OF EUROPE 171
TABLE 131 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 172
TABLE 132 REST OF EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 133 REST OF EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 173
8.2.7 EUROPE: RECESSION IMPACT 173
8.3 ASIA PACIFIC 173
FIGURE 30 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT 174
TABLE 134 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 135 ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 175
TABLE 136 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 137 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 176
8.3.1 CHINA 176
8.3.1.1 China to register highest growth in Asia Pacific market 176
TABLE 138 BIOSIMILARS APPROVED IN CHINA 177
TABLE 139 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 178
TABLE 140 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 141 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 179
8.3.2 SOUTH KOREA 179
8.3.2.1 Favorable government initiatives to support growth 179
TABLE 142 SOUTH KOREA: LIST OF APPROVED BIOSIMILARS 180
TABLE 143 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 181
TABLE 144 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 145 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 182
8.3.3 INDIA 182
8.3.3.1 Increasing biosimilar launches and approvals to support market growth 182
TABLE 146 BIOSIMILARS APPROVED AND MARKETED IN INDIA 183
TABLE 147 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 185
TABLE 148 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 149 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 186
8.3.4 JAPAN 187
8.3.4.1 Large geriatric population to drive market growth 187
TABLE 150 JAPAN: LIST OF APPROVED BIOSIMILARS 188
TABLE 151 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 189
TABLE 152 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 153 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 190
8.3.5 AUSTRALIA 191
8.3.5.1 Favorable regulatory changes and increasing disease incidence to propel growth 191
TABLE 154 AUSTRALIA: LIST OF APPROVED BIOSIMILARS 192
TABLE 155 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 194
TABLE 156 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 157 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 195
8.3.6 REST OF ASIA PACIFIC 195
TABLE 158 NEW ZEALAND: LIST OF APPROVED BIOSIMILARS 196
TABLE 159 MALAYSIA: LIST OF APPROVED BIOSIMILARS 196
TABLE 160 SINGAPORE: LIST OF APPROVED BIOSIMILARS 197
TABLE 161 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 197
TABLE 162 REST OF ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 163 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 198
8.3.7 ASIA PACIFIC: RECESSION IMPACT 199
8.4 NORTH AMERICA 199
TABLE 164 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 200
TABLE 165 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 200
TABLE 166 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 167 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 201
8.4.1 US 202
8.4.1.1 US to dominate North American biosimilars market 202
TABLE 168 US: LIST OF APPROVED BIOSIMILARS 203
TABLE 169 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 204
TABLE 170 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 171 US: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 205
8.4.2 CANADA 206
8.4.2.1 Favorable government initiatives to support market 206
TABLE 172 CANADA: LIST OF APPROVED BIOSIMILARS 206
TABLE 173 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 207
TABLE 174 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 175 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 208
8.4.3 NORTH AMERICA: RECESSION IMPACT 208
8.5 LATIN AMERICA 209
8.5.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET 209
TABLE 176 LATIN AMERICA: LIST OF APPROVED BIOSIMILARS 210
TABLE 177 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 211
TABLE 178 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 179 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 212
8.5.2 LATIN AMERICA: RECESSION IMPACT 212
8.6 MIDDLE EAST AND AFRICA 213
8.6.1 FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH 213
TABLE 180 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021–2028 (USD MILLION) 213
TABLE 181 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 182 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 214
8.6.2 MIDDLE EAST AND AFRICA: RECESSION IMPACT 215
9 COMPETITIVE LANDSCAPE 216
9.1 INTRODUCTION 216
9.2 STRATEGIES ADOPTED BY KEY PLAYERS 216
FIGURE 31 BIOSIMILARS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 216
9.3 REVENUE SHARE ANALYSIS 217
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2023 217
9.4 MARKET SHARE ANALYSIS 217
FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 218
TABLE 183 BIOSIMILARS MARKET: DEGREE OF COMPETITION 218
9.5 COMPANY EVALUATION QUADRANT, 2022 219
9.5.1 STARS 219
9.5.2 EMERGING LEADERS 219
9.5.3 PERVASIVE PLAYERS 220
9.5.4 PARTICIPANTS 220
FIGURE 34 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT, 2022 220
9.6 COMPETITIVE BENCHMARKING OF TOP 30 PLAYERS 221
9.6.1 COMPANY FOOTPRINT ANALYSIS (30 COMPANIES) 221
TABLE 184 BIOSIMILARS MARKET: COMPANY FOOTPRINT ANALYSIS 221
9.6.2 PRODUCT FOOTPRINT ANALYSIS (30 COMPANIES) 222
TABLE 185 BIOSIMILARS MARKET: PRODUCT FOOTPRINT ANALYSIS 222
9.6.3 REGIONAL FOOTPRINT ANALYSIS (30 COMPANIES) 224
TABLE 186 BIOSIMILARS MARKET: REGIONAL FOOTPRINT ANALYSIS 224
9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 225
9.7.1 PROGRESSIVE COMPANIES 225
9.7.2 STARTING BLOCKS 225
9.7.3 RESPONSIVE COMPANIES 225
9.7.4 DYNAMIC COMPANIES 226
FIGURE 35 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 226
9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES 227
TABLE 187 BIOSIMILARS MARKET: DETAILED LIST OF KEY START-UPS/SMES 227
TABLE 188 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES 227
9.9 COMPETITIVE SCENARIO AND TRENDS 228
9.9.1 PRODUCT LAUNCHES & APPROVALS 228
TABLE 189 BIOSIMILARS MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023 228
9.9.2 DEALS 229
TABLE 190 BIOSIMILARS MARKET: DEALS, JANUARY 2020–APRIL 2023 229
9.9.3 OTHER DEVELOPMENTS 230
TABLE 191 BIOSIMILARS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023 230
10 COMPANY PROFILES 231
10.1 KEY MARKET PLAYERS 231
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOVARTIS AG 231
TABLE 192 NOVARTIS AG: BUSINESS OVERVIEW 231
FIGURE 36 NOVARTIS AG: COMPANY SNAPSHOT (2022) 232
10.1.2 PFIZER INC. 236
TABLE 193 PFIZER INC.: BUSINESS OVERVIEW 236
FIGURE 37 PFIZER INC.: COMPANY SNAPSHOT (2022) 237
10.1.3 AMGEN INC. 240
TABLE 194 AMGEN INC.: BUSINESS OVERVIEW 240
FIGURE 38 AMGEN INC.: COMPANY SNAPSHOT (2022) 241
10.1.4 DR. REDDY’S LABORATORIES LTD. 244
TABLE 195 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW 244
FIGURE 39 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2022) 245
10.1.5 ELI LILLY AND COMPANY 247
TABLE 196 ELI LILLY AND COMPANY: BUSINESS OVERVIEW 247
FIGURE 40 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022) 248
10.1.6 TEVA PHARMACEUTICAL INDUSTRIES 250
TABLE 197 TEVA PHARMACEUTICAL INDUSTRIES: BUSINESS OVERVIEW 250
FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2022) 251
10.1.7 FRESENIUS KABI AG 253
TABLE 198 FRESENIUS KABI AG: BUSINESS OVERVIEW 253
FIGURE 42 FRESENIUS KABI AG: COMPANY SNAPSHOT (2022) 254
10.1.8 STADA ARZNEIMITTEL AG 257
TABLE 199 STADA ARZNEIMITTEL AG: BUSINESS OVERVIEW 257
FIGURE 43 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2022) 257
10.1.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 260
TABLE 200 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW 260
FIGURE 44 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022) 261
10.1.10 F. HOFFMANN-LA ROCHE LTD 263
TABLE 201 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW 263
FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022) 263
10.1.11 CELLTRION HEALTHCARE CO., LTD. 265
TABLE 202 CELLTRION HEALTHCARE CO., LTD.: BUSINESS OVERVIEW 265
FIGURE 46 CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT (2022) 265
10.1.12 SAMSUNG BIOLOGICS 269
TABLE 203 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW 269
FIGURE 47 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022) 270
10.1.13 COHERUS BIOSCIENCES 274
TABLE 204 COHERUS BIOSCIENCES: BUSINESS OVERVIEW 274
FIGURE 48 COHERUS BIOSCIENCES: COMPANY SNAPSHOT (2022) 274
10.1.14 BIOCON 276
TABLE 205 BIOCON: BUSINESS OVERVIEW 276
FIGURE 49 BIOCON: COMPANY SNAPSHOT (2022) 277
10.1.15 AMEGA BIOTECH 280
TABLE 206 AMEGA BIOTECH: BUSINESS OVERVIEW 280
10.1.16 APOTEX INC. 282
TABLE 207 APOTEX INC.: BUSINESS OVERVIEW 282
10.1.17 BIOCAD 283
TABLE 208 BIOCAD: BUSINESS OVERVIEW 283
10.1.18 MABXIENCE 284
TABLE 209 MABXIENCE: BUSINESS OVERVIEW 284
10.1.19 PROBIOMED 286
TABLE 210 PROBIOMED: BUSINESS OVERVIEW 286
10.1.20 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD. 287
TABLE 211 FUJIFILM KYOVA KIRIN BIOLOGICS CO., LTD.: BUSINESS OVERVIEW 287
10.1.21 INTAS PHARMACEUTICALS LTD. 288
TABLE 212 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW 288
10.1.22 RELIANCE LIFE SCIENCES 290
TABLE 213 RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW 290
10.1.23 KASHIV BIOSCIENCES, LLC 292
TABLE 214 KASHIV BIOSCIENCES, LLC: BUSINESS OVERVIEW 292
10.1.24 USV PRIVATE LIMITED 294
TABLE 215 USV PRIVATE LIMITED: BUSINESS OVERVIEW 294
10.1.25 AMNEAL PHARMACEUTICALS, INC. 295
TABLE 216 AMNEAL PHARMACEUTICALS INC.: BUSINESS OVERVIEW 295
10.2 OTHER PLAYERS 296
10.2.1 FORMYCON AG 296
10.2.2 POLPHARMA BIOLOGICS GROUP 296
10.2.3 AMPHASTAR PHARMACEUTICALS, INC. 297
10.2.4 ALVOTECH 297
10.2.5 UCB SA 298
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 299
11.1 DISCUSSION GUIDE 299
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 303
11.3 CUSTOMIZATION OPTIONS 305
11.4 RELATED REPORTS 305
11.5 AUTHOR DETAILS 306

ページTOPに戻る

Table of Contents

Summary

The global biosimilars market size is projected to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. Factors such as regulatory approvals, favorable reimbursement policies, rising demand for cost effective biosimilars is driving the market growth.
“The monoclonal antibodies product segment accounted for the highest growth rate in the biosimilars market, by drug class, during the forecast period”
In 2022, the monoclonal antibodies product segment accounted for the largest share of the biosimilars market, mainly due to the low prices of biosimilar monoclonal antibodies compared to the reference drugs and increased adoption of labs in the the treatment of cancer, autoimmune disorders, and osteoporosis. The growth of the fastest-growing segment was attributed to the rising incidence of cancer and chronic diseases globally. Increased approval for interchangeability insulin is likely to have positive impact on market.
“Oncology segment accounted for the largest share of the indication segment in 2022.”
Based on the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications. Rising demand for cancer drugs, growth hormones across various regions is propelling the growth of the market.
“Asia Pacific region is likely to grow at a faster pace.”
The biosimilars market is segmented into Europe, Asia Pacific, North America, latin America and Middle East and Africa. The APAC market is expected to be the fastest-growing regional segment during the forecast period due to the presence of numerous emerging players, less-stringent government regulations, and increasing cooperation among leading and regional players for development, manufacturing and commercialization of biosimilars.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
 Novartis AG (Switzerland)
 Pfizer Inc. (US)
 Dr. Reddy’s Laboratories Ltd. (India)
 F. Hoffmann-La Roche Ltd (Switzerland)
 Eli Lilly & Company (US)
 Amgen Inc. (US)
 Teva Pharmaceutical Industries Ltd. (Israel)
 Samsung Biologics (South Korea)
 Fresenius SE & Co. KGaA (Germany)
 Boehringer Ingelheim International GmbH. (Germany)
 STADA Arzneimittel AG (Germany)
 Coherus BioSciences (US)
 FUJIFILM Kyova Kirin Biologics Co., Ltd. (Japan)
 USV Limited (India),
 Amneal Pharmaceuticals LLC. (US)
 Celltrion Healthcare (South Korea)
 Biocon (India)
 Intas Pharmaceuticals Ltd. (India)
 Reliance Life Sciences (India)
 AMEGA Biotech (Argentina)
 Apotex, Inc. (Canada)
 BIOCAD (Russia)
 mAbxience (Spain)
 Probiomed (Mexico)
 Kashiv BioSciences, LLC (US),
 Formycon AG (Germany)
 Polpharma Biologics Group (Poland)
 Amphastar Pharmaceuticals, Inc. (US)
 Alvotech (Iceland)
 UCB SA, (Belgium)
Research Coverage:
This report provides a detailed picture of the biosimilars market. It aims at estimating the size and future growth potential of the market across different segments, such as drug class, indication and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing demand for biosimilars, launch of novel biosimilars, rising geriatric population & chronic disease incidence, abbreviated regulatory process & interchangeability), restraints (complexities in manufacturing), opportunities (emerging markets, patent expiry of blockbuster biologics and research on new indication), and challenges (excess competition & regulatory challenges) influencing the growth of biosimilars market.
• Product Development/Innovation: Detailed insights on newly launched products, and pipeline analysis of the biosimilars market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the biosimilars market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the biosimilars market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Novartis AG (Switzerland), Pfizer Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly & Company (US), Amgen Inc. (US) and among others in the biosimilars market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

MarketsandMarkets社のPharmaceuticals分野での最新刊レポート

本レポートと同じKEY WORD（biosimilars）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

バイオシミラー市場：薬剤クラス（モノクローナル抗体（アダリムマブ、インフリキシマブ、リツキシマブ、トラスツズマブ）、インスリン、エリスロポエチン、抗凝固薬、rhGH）、適応症、地域別 2028年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

MarketsandMarkets社のPharmaceuticals分野での最新刊レポート

本レポートと同じKEY WORD（biosimilars）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?